Known targets — ChEMBL curated mechanism
ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 3/20 | 0.33 |
| ▸ | NPC1 | O15118 | 2/20 | 0.33 |
| ▸ | PGR | P06401 | 1/20 | 0.33 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3854799 | 0.78 | CYP1A2 (0.39) | KMT2AMEN1ALDH1A1MAPTL3MBTL1 | |
| Hydrochloric Acid SCHEMBL3851014 | 0.76 | KMT2A (0.62) | CYP3A4BAZ2BKMT2AMEN1ALDH1A1 | |
| SCHEMBL4625960 | 0.73 | KMT2A (0.54) | CYP3A4BAZ2BKMT2AALDH1A1MAPT | |
| Iodide SCHEMBL6849471 | 0.72 | KMT2A (0.53) | CYP3A4BAZ2BKMT2AALDH1A1MAPT | |
| SCHEMBL6849554 | 0.67 | KMT2A (0.46) | CYP3A4BAZ2BKMT2AALDH1A1MAPT | |
| SCHEMBL14622022 | 0.66 | APOBEC3A (0.46) | KMT2AMEN1ALDH1A1MAPTRAB9A | |
| Iodide SCHEMBL6849559 | 0.66 | KMT2A (0.45) | CYP3A4BAZ2BKMT2AALDH1A1MAPT | |
| SCHEMBL2241437 | 0.65 | KMT2A (0.71) | CYP3A4BAZ2BKMT2AMEN1ALDH1A1 | |
| SCHEMBL9142779 | 0.64 | KMT2A (0.59) | KMT2AMEN1ALDH1A1MAPTRAB9A | |
| Hydrochloric Acid SCHEMBL3854519 | 0.63 | ALDH1A1 (0.61) | KMT2AMEN1ALDH1A1MAPTRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070099892-A1 | Cyanomethyl substituted thiazoliums and imidazoliums and treatments of disorders associated with protein aging | SYNVISTA THERAPEUTICS, INC. | 2007-05-03 | — | — | US | claimed |
| EP-1303501-B1 | CYANOMETHYL SUBSTITUTED THIAZOLIUMS AND IMIDAZOLIUMS AND TREATMENTS OF DISORDERS ASSOCIATED WITH PROTEIN AGING | ALTEON INC (US) | 2005-09-21 | — | — | EP | claimed |
| US-20050032865-A1 | Cyanomethyl substituted thiazoliums and imidazoliums and treatments of disorders associated with protein aging | WAGLE DILIP R (IN) | 2005-02-10 | — | — | US | claimed |
| EP-2085086-A2 | Method for treating congestive heart failure or diabetic nephropathy | Synvista Therapeutics, Inc. (US) | 2009-08-05 | — | — | EP | disclosed |
| US-20090124674-A1 | Method for treating congestive heart failure | SYNVISTA THERAPEUTICS, INC. (US) | 2009-05-14 | — | — | US | disclosed |
| US-20090124673-A1 | Method for treating diabetic nephropathy | SYNVISTA THERAPEUTICS , INC. (US) | 2009-05-14 | — | — | US | disclosed |
| US-7432254-B2 | Method for treating glaucoma IC | SYNVISTA THERAPEUTICS, INC. (US) | 2008-10-07 | — | — | US | disclosed |
| US-20070099892-A1 | Cyanomethyl substituted thiazoliums and imidazoliums and treatments of disorders associated with protein aging | SYNVISTA THERAPEUTICS, INC. | 2007-05-03 | — | — | US | disclosed |
| US-20070043016-A1 | Method of treating fibrotic diseases or other indications with imidazolium agents | SYNVISTA THERAPEUTICS, INC. | 2007-02-22 | — | — | US | disclosed |
| US-7166625-B2 | Method for treating fibrotic diseases and other indications | ALTEON, INC. (US) | 2007-01-23 | — | — | US | disclosed |
| EP-1305024-A4 | METHOD FOR TREATING FIBROTIC DISEASES OR OTHER INDICATIONS IC | ALTEON INC (US) | 2006-03-22 | — | — | EP | disclosed |
| EP-1305024-A1 | METHOD FOR TREATING FIBROTIC DISEASES OR OTHER INDICATIONS IC | Alteon, Inc. (US) | 2003-05-02 | — | — | EP | disclosed |
| EP-1303501-A1 | CYANOMETHYL SUBSTITUTED THIAZOLIUMS AND IMIDAZOLIUMS AND TREATMENTS OF DISORDERS ASSOCIATED WITH PROTEIN AGING | Alteon, Inc. (US) | 2003-04-23 | — | — | EP | disclosed |
| US-20020177586-A1 | Method for treating fibrotic diseases or other indications ID | SYNVISTA THERAPEUTICS, INC. | 2002-11-28 | — | — | US | disclosed |
| US-20020160993-A1 | Method for treating glaucoma IC | SYNVISTA THERAPEUTICS, INC. | 2002-10-31 | — | — | US | disclosed |
| US-20020103182-A1 | Cyanomethyl substituted thiazoliums and imidazoliums and treatments of disorders associated with protein aging | SYNVISTA THERAPEUTICS, INC. | 2002-08-01 | — | — | US | disclosed |
| WO-2002053158-A1 | METHOD FOR TREATING GLAUCOMA IB | ALTEON, INC. (US) | 2002-07-11 | — | — | WO | disclosed |
| US-20020068729-A1 | Method for treating fibrotic diseases or other indications IC | ALTEON, INC. | 2002-06-06 | — | — | US | disclosed |
| WO-2002008210-A1 | CYANOMETHYL SUBSTITUTED THIAZOLIUMS AND IMIDAZOLIUMS AND TREATMENTS OF DISORDERS ASSOCIATED WITH PROTEIN AGING | ALTEON, INC. (US) | 2002-01-31 | — | — | WO | disclosed |
| WO-2002007725-A1 | METHOD FOR TREATING FIBROTIC DISEASES OR OTHER INDICATIONS IC | ALTEON, INC. (US) | 2002-01-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020103182-A1 | Cyanomethyl substituted thiazoliums and imidazoliums and treatments of disorders associated with protein aging | ABAT, TTR, TUFM | CYP3A4 3380/4885BAZ2B 2407/4885KMT2A 2996/4885 |
| US-20020160993-A1 | Method for treating glaucoma IC | CHAT, MYOC, GAP43 | CYP3A4 3822/4885BAZ2B 4849/4885KMT2A 4535/4885 |
| US-20020068729-A1 | Method for treating fibrotic diseases or other indications IC | MMP1, COL1A1, COL2A1 | CYP3A4 4055/4885BAZ2B 2428/4885KMT2A 4545/4885 |
| US-20090124673-A1 | Method for treating diabetic nephropathy | REN, SLC5A2, SLC5A1 | CYP3A4 3393/4885BAZ2B 4700/4885KMT2A 4493/4885 |
| US-20020177586-A1 | Method for treating fibrotic diseases or other indications ID | MMP1, COL1A1, COL2A1 | CYP3A4 3634/4885BAZ2B 2557/4885KMT2A 4326/4885 |
| US-20050032865-A1 | Cyanomethyl substituted thiazoliums and imidazoliums and treatments of disorders associated with protein aging | ABAT, TUFM, TTR | CYP3A4 3570/4885BAZ2B 2196/4885KMT2A 2897/4885 |
| US-20070043016-A1 | Method of treating fibrotic diseases or other indications with imidazolium agents | MMP1, COL1A1, EPX | CYP3A4 1297/4885BAZ2B 617/4885KMT2A 4075/4885 |
| US-20090124674-A1 | Method for treating congestive heart failure | TNNI3, TNNT2, FABP3 | CYP3A4 3075/4885BAZ2B 4693/4885KMT2A 4520/4885 |
| US-20070099892-A1 | Cyanomethyl substituted thiazoliums and imidazoliums and treatments of disorders associated with protein aging | ABAT, TUFM, TTR | CYP3A4 3570/4885BAZ2B 2196/4885KMT2A 2897/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.